Pigmentary disorders


Depigmentation therapy refers to medical treatments that remove skin pigmentation. Depigmentation therapy is used in someone that has widespread, but incomplete, vitiligo on the face and/or other sites, in an attempt to improve their appearance. The most commonly used depigmenting agent is monobenzyl ether of hydroquinone (MBEH). If the patient cannot tolerate MBEH, or if treatment fails, combination therapies or other treatments may be considered. Depigmentation therapy may be considered in the management of treatment resistant vitiligo affecting more than 50% of the body surface area or affecting cosmetically sensitive, exposed body sites


    Related Conference of Pigmentary disorders

    May 25-26, 2021

    26th world Congress & expo on Dermatology

    Osaka, Japan
    June 21-22, 2021

    22nd World Dermatology Congress

    Tokyo, Japan
    July 12-13, 2021

    21st European Dermatology Congress

    Amsterdam, Netherlands
    March 18-19, 2021

    2nd World Dermatology and Aesthetic Congress

    Dubai, UAE
    July 26-27, 2021

    4th World Cosmetic and Dermatology Congress

    Paris, France
    September 06-07, 2021

    World Congress on Skin care, Dermatology and Allergic Diseases

    Prague, Czech Republic
    October 05-06, 2021

    26th Asia-Pacific Dermatology Conference

    Auckland, Newzealand
    October 05-06, 2021

    2nd International Dermatologists Annual Meeting

    Auckland, Newzealand
    October 21-22, 2021

    5th World Dermatology Congress

    London, UK
    November 02-03, 2021

    Asian Aesthetic and Dermatology congress

    Sydney, Australia
    November 02-03, 2021

    Global Meet on Skin Care and Plastic Aesthetics

    Sydney, Australia
    January 28-29, 2022

    2nd Global Summit on Skincare and Plastic Aesthetic

    Singapore, Singapore

    Pigmentary disorders Conference Speakers

    Recommended Sessions

    Related Journals

    Are you interested in